Trials / Terminated
TerminatedNCT00484536
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 232 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDP323 | 250 mg capsules, 500 mg bid (1000 mg/day) |
| DRUG | placebo | capsules, once daily |
| DRUG | CDP323 | 250 mg Capsules, 500 mg, once daily |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-11-01
- Completion
- 2010-07-01
- First posted
- 2007-06-11
- Last updated
- 2011-09-12
Locations
71 sites across 11 countries: United States, Belgium, Canada, Finland, France, Germany, Hungary, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00484536. Inclusion in this directory is not an endorsement.